Newly developed retatrutide, a combined-action medication targeting both GLP-1 and GIP receptors, is creating considerable interest within the healthcare community. Initial clinical research have demonstrated substantial decreases in physical weight and advancements in metabolic markers for individuals with obesity . Researchers believe this groun